Advertisement

Clindamycin Injection

[09 June 2016]

Products Affected - Description

Clindamycin phosphate injection, Alvogen (formerly Hospira)
150 mg/mL, 2 mL ADD-Vantage vial, 25 count (NDC 00409-4053-03) - discontinued
150 mg/mL, 2 mL vial, 25 count (NDC 00409-4050-01) - discontinued
150 mg/mL, 4 mL ADD-Vantage vial, 25 count (NDC 00409-4054-03) - discontinued
150 mg/mL, 4 mL vial, 25 count (NDC 00409-4051-01) - discontinued
150 mg/mL, 6 mL ADD-Vantage vial, 25 count (NDC 00409-4055-03) - discontinued
150 mg/mL, 60 mL bulk vial, 1 count (NDC 00409-4197-01) - discontinued
 
Clindamycin phosphate injection, Fresenius Kabi
150 mg/mL, 60 mL vial, 1 count (NDC 63323-0282-60)

Reason for the Shortage

  • Akorn cannot provide a reason for the shortage.
  • Pfizer states the Cleocin Add-Vantage vials are on shortage due to manufacturing delays.
  • Hospira divested clindamycin injection to Alvogen in September 2015. Alvogen will sell Hospira labeled product until supplies are gone and then will sell Alvogen labeled product.
  • Sandoz had clindamycin injection on shortage due to increased demand.
  • Sagent has clindamycin injection on shortage due to manufacturing delays.

Available Products

Cleocin injection, Pfizer
150 mg/mL, 2 mL vial, 25 count (NDC 00009-0870-26)
150 mg/mL, 4 mL ADD-Vantage vial, 25 count (NDC 00009-3124-03)
150 mg/mL, 4 mL vial, 25 count (NDC 00009-0775-26)
150 mg/mL, 6 mL ADD-Vantage vial, 25 count (NDC 00009-3447-03)
150 mg/mL, 6 mL vial, 25 count (NDC 00009-0902-18)
150 mg/mL, 60 mL vial, 5 count (NDC 00009-0728-09)
300 mg/50 mL premixed bags, 24 count (NDC 00009-3381-02)
600 mg/50 mL premixed bags, 24 count (NDC 00009-3375-02)
900 mg/50 mL premixed bags, 24 count (NDC 00009-3382-02)
 
Clindamycin phosphate injection, Akorn
300 mg/50 mL, premixed bottle, 1 count (NDC 17478-0120-50)
600 mg/50 mL, premixed bottle, 1 count (NDC 17478-0121-50)
900 mg/50 mL, premixed bottle, 1 count (NDC 17478-0122-50)

Clindamycin phosphate injection, Alvogen
150 mg/mL, 2 mL ADD-Vantage vial, 25 count (NDC 47781-0462-69)
150 mg/mL, 2 mL vial, 25 count (NDC 00409-4050-01) - discontinued
150 mg/mL, 2 mL vial, 25 count (NDC 47781-0459-68)
150 mg/mL, 4 mL ADD-Vantage vial, 25 count (NDC 44781-0463-69)
150 mg/mL, 4 mL vial, 25 count (NDC 47781-0460-68)
150 mg/mL, 6 mL ADD-Vantage vial, 25 count (NDC 47781-0464-69)
150 mg/mL, 6 mL vial, 25 count (NDC 00409-4052-01)
150 mg/mL, 60 mL bulk vial, 1 count (NDC 47781-0465-70)
 
Clindamycin phosphate injection, Fresenius Kabi
150 mg/mL, 2 mL vial, 25 count (NDC 63323-0282-02)
150 mg/mL, 4 mL vial, 25 count (NDC 63323-0282-04)
150 mg/mL, 6 mL vial, 25 count (NDC 63323-0282-06)

Clindamycin phosphate injection, Sagent
150 mg/mL, 2 mL vial, 25 count (NDC 25021-0115-02)
150 mg/mL, 4 mL vial, 25 count (NDC 25021-0115-04)
150 mg/mL, 6 mL vial, 25 count (NDC 25021-0115-06)
150 mg/mL, 60 mL bulk vial, 1 count (NDC 25021-0115-51)
 
Clindamycin phosphate injection, Sandoz
300 mg/50 mL premixed container, 24 count (NDC 00781-3288-09)
900 mg/50 mL premixed container, 24 count (NDC 00781-3290-09)
900 mg/50 mL, premixed container, 24 count (NDC 00781-3290-09)

Estimated Resupply Dates

Fresenius Kabi has clindamycin 150 mg/mL 60 mL bulk vials on back order and the company estimates a release date of 3rd quarter 2016. Product with short expiration dating (< 5 months) is available for drop shipment.

Related Shortages

Updated

June 9, April 14, February 24, January 27, 14 and 6, 2016; December 15, November 5 and 4, October 19, September 17, July 21, June 25, April 30 and 17, March 30, 23 and 9, February 12, January 14, 2015; December 29, 22, 17 and 5, November 24 and 4, October 23 and 10, September 24, 12 and 3, August 15 and 8, June 12, May 23 and 5, April 23 and 7, March 26, 11 and 5, February 21 and 10, January 24 and 14, 2014; December 27 and 18, November 21 and 6, October 23, 14 and 7, September 17, August 28 and 7, July 3, June 13, 2013, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing